Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from Brokerages

Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $18.60.

ATYR has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating for the company. Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partners assumed coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company.

Atyr PHARMA Trading Up 7.8 %

Shares of Atyr PHARMA stock opened at $3.60 on Friday. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The business has a 50 day moving average price of $3.29 and a 200 day moving average price of $3.40. The company has a market capitalization of $319.89 million, a P/E ratio of -3.83 and a beta of 0.95.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Sell-side analysts anticipate that Atyr PHARMA will post -0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ATYR. JPMorgan Chase & Co. increased its position in shares of Atyr PHARMA by 467.8% in the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock worth $646,000 after acquiring an additional 147,092 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in Atyr PHARMA during the 4th quarter worth $144,000. American Century Companies Inc. acquired a new stake in Atyr PHARMA in the 4th quarter valued at $319,000. Victory Capital Management Inc. purchased a new position in Atyr PHARMA in the fourth quarter valued at about $37,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Atyr PHARMA during the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.